Weight loss covered by Medicare

Currently Shapely serves adults age 18 and older in the states of California, Florida, New York, and Texas. We will soon be expanding to all 50 US states!

Shapely is excited to now be accepting original Medicare and most Medicare Advantage PPO plans in California, Florida, New York and Texas! We navigate insurance on your behalf and are able to work with the vast majority of insurances to get cost-effective access to GLP-1 medications.

As of July 1, 2026 eligible patients with Medicare Part D can access GLP-1 medications including Wegovy®, Zepbound® and Foundayo for just $50 per month through the Medicare GLP-1 Bridge program. You can learn more about that program here. Outside of the GLP-1 Bridge Program, Medicare also covers GLP-1 medications for (1) diabetic patients, (2) patients with cardiovascular disease such as heart attack or stroke, and (3) patients with moderate to severe obstructive sleep apnea.

Medicare also covers visits with our expert team of providers and dietitians, as well as a digitial smart scale used to remotely monitor your weight loss journey. You may be responsible for any cost-sharing, such as co-pays, deductibles, and co-insurances.

Our team will review your benefits and eligibility in advance so you understand your coverage and potential out-of-pocket costs before starting care.

If you don’t have insurance, or if your insurance doesn’t cover your medication, there are still options.

Shapely can help patients access self-pay programs for FDA-approved medications, such as Wegovy® through NovoCare® and Zepbound® through Lilly Direct®, which may offer discounted pricing for eligible patients.

In some cases, your provider may determine that a compounded medication is clinically appropriate based on your individual needs. When prescribed, compounded medications are offered on a self-pay basis, with pricing starting at $99 per month for compounded semaglutide and $166 per month for compounded tirzepatide.

‍Shapely is not affiliated with Novo Nordisk, Eli Lilly, or their patient programs. Compounded medications are not FDA-approved and are prepared by state-licensed pharmacies based on a provider’s clinical judgment.

Patients on FDA-approved GLP-1 medications like Ozempic and Wegovy can lose up to 15% of their weight. With Mounjaro and Zepbound, weight loss can be as much as 20%. Note that results are not guaranteed and may vary. With other medications, weight loss can be up to 10%. Ultimately, your weight loss journey is a personal one, and your Shapely team will be by your side to help you achieve your best results.

Typically, we find that patients taking FDA-approved GLP-1 agonists such as Ozempic® and Wegovy® will lose 10% of weight by 6 months and 15% within 1 year. Results will vary by patient, intervention, and medication prescribed (if appropriate). We find that patients benefit from at least a 12 month comprehensive weight-loss program to establish the proper habits to sustain long-term weight loss

If you are not a good candidate for GLP-1 agonists, our physicians will offer different modalities of weight loss for you, including alternative medications, lifestyle modification, continuous glucose monitoring, and other tools.

Recent labs are strongly recommended (but not required) prior to initiation of most weight loss medications. We will either order labs for you or accept labs completed within 12 months prior to program enrollment. Labs are  typically covered by insurance though there may be a co-pay.